IRONWOOD PHARMACEUTICALS, INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 2.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2025-03-31
- IRONWOOD PHARMACEUTICALS, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2024 was 2.50%.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 6 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month |
|---|---|---|
| 2024-12-31 | 2.50% 10-K · filed 2025-03-31 | |
| 2023-12-31 | 2.70% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |